Home/Regulatory/Policy
All Articles
November 25, 2019

Shoppable Services: Price Transparency Era’s First Real Business Bellwether

Many pharma executive and marketing leaders actively monitor the pricing transparency conversation in search of the meaningful insights that can truly impact their business performance. And while much public attention has been paid to items such as “drug costs in TV commercials” and “CEO testimony before Congress,” little evidence exists

August 29, 2019

EVP Wendy Blackburn: 5 Options for Managing the DTC Transparency Debacle

Drug pricing is a hot button issue, including the pricing transparency battle, and it's not going away anytime soon. On July 8, U.S. District Court Judge Amit Mehta ruled that the Department of Health and Human Services had overstepped its authority in requiring pricing disclosures, stating, “That policy very well

July 31, 2019

Complying With Colorado’s New Drug Price Transparency Law

This POV describes Colorado House Bill 19-1131 and how it could affect pharma marketers. The bill requires that any one-to-one communications between pharmaceutical representatives (or anyone communicating on their behalf) and prescribers must include written information about the wholesale cost of a drug, as well as the names of at least three generic equivalents. The law goes into effect on August 2, 2019.

July 16, 2019

California’s New Data Privacy Law: New Thinking on its Implications for Pharma

Last fall, we published a POV called “Should Pharma Care About California’s New Data Privacy Law?” Since then, we’ve been monitoring the legislative process and the discussions and reactions of opinion leaders. This updated POV provides the latest thinking on this law and its implications for pharma marketers.

June 6, 2019

Five Issues in Washington for Pharma to Watch

At the Coalition’s Rising Leaders conference on healthcare policy in Washington, D.C. May 22, a diverse set of speakers provided updates and predictions, and discussed the potential impact of the many significant healthcare policy decisions pending on Capitol Hill. This POV provides an overview of five issues to watch that were highlighted at the conference, as well as strategies for addressing them.

May 16, 2019

New List Price Mandate for DTC Television Advertising

On May 8, 2019, the Trump administration announced that the Centers for Medicare & Medicaid Services (CMS) would require drugs covered by Medicare or Medicaid to include a list price in any DTC television commercial within 60 days of the announcement, if their list price is at least $35 for a month’s supply or a course of treatment. The ruling is virtually the same as the one proposed in October 2018, and only products that advertise on TV are affected directly by the ruling. This POV provides a brief summary of the background to this ruling, a summary of its specifics, some reactions to it, and our recommendations to clients in its wake.

Load More Posts